Yong Ben appointed Chief Medical Officer of BioAtla

BioAtla, announced that Dr. Yong Ben has been appointed as Chief Medical Officer.

Dr. Yong Ben joins BioAtla with over 20 years of industry and academic experience in oncology. During his 13 years of increasing responsibility in biotechnology and pharmaceutical companies, he has led wide-spectrum clinical development efforts from phase 1 to phase 3 clinical trials, from strategy planning to study execution and BLA/NDA submissions. Prior to his career at AstraZeneca, Dr. Ben was Medical Director, Oncology Clinical Research at Millennium Pharmaceuticals where, in addition to leading the pivotal global phase 3 study for ixazomib in refractory/relapsed multiple myeloma, he was clinical lead in the orteronel and alisertib programs. Prior to that, Dr. Ben was Lead Clinician/Global Medical Monitor, Clinical Development for the Pfizer Oncology Business Unit and earlier was Project Manager, Asia Research & Development for Pfizer Global Research & Development. Dr. Ben began his career in industry with Shanghai Sunway Biotech Co., a leader in the field of oncolytic viruses. Dr. Ben started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center Research Institute.  Dr. Ben received his medical degree from Norman Bethune Medical University and his MBA from the University of California, San Diego.

BioAtla chairman, president and CEO, Jay M. Short said that Dr. Ben’s experience and proven capabilities in leading the clinical development of innovative oncology products over a range of indications greatly enhances BioAtla’s ability to design, implement, and execute clinical programs evolving from our CAB platform.